Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The effectiveness of cyclic and continuous oral clodronate therapy on bonedensity and markers in osteopenic postmenopausal women
Autore:
Tsai, KS; Hsu, SHJ; Yang, RS; Cheng, WC; Chieng, PU;
Indirizzi:
Natl Taiwan Univ, Coll Med, Dept Lab Med, Taipei 10016, Taiwan Natl TaiwanUniv Taipei Taiwan 10016 Dept Lab Med, Taipei 10016, Taiwan Natl Taiwan Univ, Coll Med, Dept Orthoped, Taipei, Taiwan Natl Taiwan Univ Taipei Taiwan Coll Med, Dept Orthoped, Taipei, Taiwan Natl Taiwan Univ, Coll Med, Dept Radiol, Taipei, Taiwan Natl Taiwan Univ Taipei Taiwan v, Coll Med, Dept Radiol, Taipei, Taiwan
Titolo Testata:
CALCIFIED TISSUE INTERNATIONAL
fascicolo: 5, volume: 64, anno: 1999,
pagine: 384 - 388
SICI:
0171-967X(199905)64:5<384:TEOCAC>2.0.ZU;2-L
Fonte:
ISI
Lingua:
ENG
Soggetto:
HORMONE REPLACEMENT THERAPY; LINKED N-TELOPEPTIDES; MINERAL DENSITY; I COLLAGEN; OSTEOPOROSIS; ALENDRONATE; IMMUNOASSAY; RESORPTION; TURNOVER; MASS;
Keywords:
clodronate; cyclic; continuous; bone resorption markers; postmenopausal osteopenia;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
24
Recensione:
Indirizzi per estratti:
Indirizzo: Tsai, KS NatlTaiwann Univ, Coll Med, Dept Lab Med, 7 Chung Shan S Rd, Taipei 10016, Natl Taiwan Univ 7 Chung Shan S Rd Taipei Taiwan 10016 ei 10016,
Citazione:
K.S. Tsai et al., "The effectiveness of cyclic and continuous oral clodronate therapy on bonedensity and markers in osteopenic postmenopausal women", CALCIF TIS, 64(5), 1999, pp. 384-388

Abstract

Bisphosphonates have been used effectively to treat established osteoporosis and prevent postmenopausal bone loss. However, the optimal manner of itsadministration-whether cyclic or continuous-has not been well established. This study investigated the efficacy of cyclic and continuous oral administration of clodronate in 54 newly identified osteopenic postmenopausal women in a randomized, double-blind, crossover fashion. The participants were randomly separated into two groups. The cyclic group (n = 29) received 800 mg twice daily of oral clodronate for 2 weeks every 3 months for the first 12 months followed by placebo for the second 12 months. The continuous group(n = 25) received placebo in the first 12 months and ingested 400 mg of clodronate once daily for the second 12 months. The urinary amino-terminal (NTX(TM)) and carboxy-terminal (CrossLaps(TM)) cross-linked fragments of typeI collagen, both markers of bone resorption, showed a marked decrease (25-50%) with both regimens during the period of active treatment. In the cyclic group, the levels of these two markers increased in the second 12 months with placebo, but did not return to the baseline completely. However, bone mineral density (BMD), determined by dual-energy X-ray absorptiometry (DXA), showed no significant change of BMD at various sites after 1 year of active treatment in both groups. Thoracic and lumbar spine X-ray showed no new vertebral fracture in either group after 2 years of treatment. With the twotreatment protocols in this study, oral clodronate was effective in decreasing postmenopausal bone resorption, causing no significant changes in BMD at various sites.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/11/20 alle ore 12:54:50